Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
EPIVAC
HIV/AIDS
Framework programme: 6
Call: 4
Project number: LSHP-CT-2006-037651
EC contribution: € 2,400,000
Duration: 36 month
Type: STREP
Starting date: 1st January 2007
Graphic element Development of a multi-step Improved Epidermis Specific Vaccine Candidate against HIV/AIDS
Keywords: Vaccines; DNA Therapy; Epidermal Genetic Vaccination; HIV Infection and AIDS

Summary:

More than 40 million people are currently infected with HIV1, mostly coming from developing countries resulting in an urgent need for effective and affordable treatment of HIV1 infections. The main objective of the project is to develop an efficient genetic vaccine candidate for therapeutic and preventative use against HIV/AIDS.

The vaccine planned, should be capable of inducing cell-mediated and humoral immunity against the virus and virally infected cells in different phases of the viral life-cycle.

DNA vaccines could fulfil these requirements if rendered more efficient. To this aim, a combination of complementary technologies by four SMEs will be used. The novel DNA vaccination technology will combine:

  1. The restricted expression of the multi-epitope/multivalent HIV antigens in specific cells of the epidermis
  2. A micro-needle array-based injection device for reproducible and efficient delivery into the epidermis
  3. The EPI-GTU® technology that allows strong and long-term expression using segregation/partitioning function of the Bovine papillomavirus type 1
  4. The plasmo-VLP® technology that allows an expression of the immunogens within and onto virus-like-particles
  5. The adjuvant effect of different cytokines.

The step-by-step combination of these technologies will be evaluated at the laboratories of the three academic partners by using state of the art methods.

The initial evaluation of vaccine efficacy will be performed on mice and pigs and will be ultimately validated in Cynomolgus monkeys. EPIVAC aims to conduct its preclinical development up to the GMP production phase. Testing of numerous vector batches will be aimed towards having enough suitable material ready for evaluation in clinical trials.

Background:

The Human Immunodeficiency Virus (HIV) induces chronic infection in patients, eventually leading to deterioration of the immune system and the onset of immune deficiency. HIV induces significant cell-mediated and humoral immune responses, which considerably reduce viral titre after initial burst of the HIV1 replication and spread in the body. These naturally induced immune responses only partially control HIV spread and in fact there are no clearly documented cases of true clearance of the viral infection.

Nevertheless, it is possible that the triggering of additional immune responses, notably through the presentation of modified HIV antigens, could generate different types of immune responses that could contribute towards better control of the infection and thus improve clinical evolution and reduce viral transmissibility.

The quality and intensity of the humoral or cellular immune responses required for efficacious preventative or therapeutic vaccinations vary, depending on the target infectious agents. Preventative vaccines against acute viral infections often rely on strong neutralising antibody responses, while therapeutic vaccines against chronic infectious diseases often rely on cytotoxic responses capable of eliminating infected cells.

Most antiviral vaccines in current use are based on homologous inactivated or attenuated viral particles, i.e. attenuated measles virus for measles vaccination. This establishes that packaging antigens in/onto particles is one of the most efficient ways of triggering efficient antiviral immune responses. Some of the most promising new vaccines have been designed and developed in the field of DNA vaccination. DNA vaccines are low in cost, stable and easy to produce whist offering the possibility to combine several antigens when required. However, it appears that DNA vaccination, typically induces cellular immunity, but rarely or inefficiently neutralising antibodies that often play a major role in protection against viruses (Tuteja et al., 1999).

Based on this knowledge, the EPIVAC Project proposes the concept of combining the advantages of various vaccines by engineering them into single vectors, i.e. by designing plasmids that harbour the genetic code necessary for the production of recombinant viral particles, which further target the skin as a preferential site for genetic immunisation.

Aim:

EPIVAC aims to generate a multi-step, improved, efficient and affordable DNAbased preventative and therapeutic vaccine against HIV. The first goal of EPIVAC is the development of a reliable, reproducible and robust delivery system. This will include micro-needle arrays and an injection device for the controlled delivery of the GTU®-based vector system and for celltype- specific epidermal expression of the genes of interest in epidermal differentiating keratinocytes, Langerhans cells and melanocytes. The plasmids and genes of interest used in these studies will allow for the quantitative evaluation of the efficiency and kinetics of delivery of plasmid DNA into the epidermis and epidermal cells. Further, to follow the process of diffusion, degradation and intracellular up-take and onset of biological activity of the delivered expression system in specific cells of the epidermis will be assessed. The plasmids used will carry the site-specific fluorescent labels for the monitoring of DNA delivery into the epidermis as well as the diffusion and degradation of the plasmid.

The second goal of the EPIVAC project will be to analyse the effect of different HIV1 antigen expression in different cells of the epidermis on the nature and breadth of the induced immune response.

One major problem in developing an AIDS vaccine is the lack of knowledge regarding immune mechanisms for protection against HIV1 infection and for removing the virus from the body. Another goal of this project is to contribute towards the identification of some immune correlates of protection during the evaluation of vaccine efficacy in non-human primates.

The induced immune response triggered by the vaccination will be characterised qualitatively and quantitatively towards every viral target protein. The immunised animals will be challenged after immunisations with the hybrid SHIV, and analysed for control, clearance and protection.

Expected results:

  1. New devices and modalities for DNA delivery to the epidermis
  2. Generate improved DNA-based vaccines combining the advantages of GTU vectors for long-term expression and plasmo-VLP vectors for the presentation of antigens onto VLPs
  3. Generation of new proprietary HIV antigens based on the EPIVAC optimised vector.

Potential applications:

  1. Epidermal genetic vaccinations; Improved treatment of HIV infection and AIDS by using nanotechnology
  2. Improved standards for vaccination in large animals, notably by using swines that are not often used in vaccine development and which could become interesting alternatives to the use of non-human primates for challenge experiments.

Coordinator:

Ioana Stanescu
FIT Biotech Plc
Biokatu 8, 33520
Tampere,
Finland
Tel: + 358 3 3138 7020
Fax: + 358 3 3138 7050
E-mail: ioana.stanescu@fitbiotech.com
Website: www.fitbiotech.com

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Henrik Hellqvist Silex Microsystems AB
Bruttovägen 1, Järfälla 595,
17526,
Sweden
Tel: +468 5802 4900
Fax: + 468 5802 4901
E-mail: henrik.hellqvist@silexmicrosystems.com
Website: www.silexmicrosystems.com
3Evgeny BerikEstla Ltd.
Riia 185,
Tartu 51014,
Estonia
Tel: + 372 742 8891
Fax. + 372 742 8891
E-mail: evegeny@estla.com
Website: www.estla.com
4Charlotte Dalba EPIXIS SA
5 rue des Wallons,
Paris 75013,
France
Tel: + 33 1 421 76520
Fax: + 33 1 421 76516
E-mail: cd@epixis.com
Website: www.epixis.com
5David Klatzmann University of Pierre and Marie Curie
4 Place Jussieu,
Paris 75252,
France
Tel:+ 3 1 42 177 470
Fax: + 33 1 42 177 441
E-mail: david.klatzmann@chups.jussieu.fr
Website: www.upmc.fr
6Mart UstavTartu University Institute of Technology
Ulikooli 18,
Tartu 50090,
Estonia
Tel: + 372 737 4800
Fax: + 372 737 4900
E-mail: mart.ustav@ebc.ee
Website: www.tuit.ut.ee
7Roger Le Grand French Atomic Energy Commission
31-33 Rue de la Federation,
F-75752 Paris,
France
Tel: + 33 1 4654 73 74
Fax: + 33 1 46 54 77 26
E-mail: roger.le-grand@cea.fr
Website: www.cea.fr

 
 
top
Graphic element